Isabelle Rivière received her Ph. D. in Cellular and Molecular Biology from the University of Paris in 1993. She initiated her graduate studies in the Interferon Research Group at the Institut Curie, Paris and completed her thesis work in the laboratory of Richard Mulligan,Ph.D at the Whitehead Institute for Biomedical Research, Cambridge, MA.
During this time, she developed the MFG/SFG-based gamma-retroviral vectors for in vivo long-term expression of transgenes in hematopoietic cells, which are currently used in multiple clinical trials for the treatment of hereditary blood disorders and cancer. She subsequently worked as a postdoctoral fellow in the laboratory of Dan Littman, MD, Ph.D at New York University, New York, NY.
Her studies focused on the regulation of cytokines produce by T helper lymphocytes in vivo, based on a mouse model she developed to track IL-4 secreting T cells using homologous recombination in embryonic stem cells. Dr. Rivière joined the faculty of the Memorial Sloan-Kettering Cancer Center (MSKCC) in 1999.
She is currently the Director of the Cell Therapy and Cell Engineering Facility where she investigates novel strategies for cell therapies and immunotherapies to increase or retarget the immune response against tumors and treat hematological disorders. Her laboratory has developed multiple processes for clinical-grade gamma-retroviral and lentiviral vector production as well as hematopoietic and T cell manufacturing.
Dr. Rivière serves on the editorial board of Molecular Therapy: Methods and Clinical Development and on multiple committees of the Association of Academic Biologics Manufacturers (AABM), the International Society for Cellular Therapy (ISCT) and the American Society of Gene & Cell Therapy (ASGCT).